Uterine Cancer pp 105-121 | Cite as

Pathology of Endometrial Hyperplasia and Carcinoma

  • Bharat Rekhi
  • Kedar K. Deodhar
  • Santosh Menon


Endometrial cancer forms the fifth most commonly diagnosed cancer in women worldwide and the fourth most commonly diagnosed cancer in the United States [1, 2]. On an average, 154 cases are annually received at Tata Memorial Hospital (TMH), as per TMH Based Cancer Registry (2002–2005) [3]. These occur mostly in postmenopausal women. This chapter shall focus upon pathology of endometrial hyperplasias and carcinomas, including various subtypes; diagnostic challenges involved during histopathological reporting; overcoming these challenges; insights into relevant immunohistochemistry; molecular updates and finally, formulation of a scientifically correct and clinically relevant/viable histopathology report, including diagnosis.


Lynch Syndrome Endometrial Carcinoma Myometrial Invasion Endometrial Hyperplasia Endometrial Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



I am grateful to the pathology residents of TMH, Dr. Chhavi Gupta, Dr. Aekta Dubey, and Dr. Sushant Vinarkar, who helped me in procuring gross images of specimens and in retrieving histopathology slides for microscopic images. I also thank Dr. Amita Maheshwari, Professor, Surgical Oncology (Gynaecology), for providing gross image of a case of endometrial carcinoma.


  1. 1.
    Parazzini F, Francesci S. The epidemiology of female genital tract cancers. Int J Gynecol Cancer. 1997;7:169–81.CrossRefGoogle Scholar
  2. 2.
    Society AC. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:4–64.CrossRefGoogle Scholar
  3. 3.
    Dinshaw KA, Ganesh B. Hospital based cancer registry- annual report 2008. Mumbai: Tata Memorial Hospital. p. 1–110.Google Scholar
  4. 4.
    Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. Atlas of tumor pathology. 3rd Series. Fascicle 3. Washington, DC: Armed Forces Institute of Pathology; 1992. p. 13–4.Google Scholar
  5. 5.
    Zaino RJ. Interpretation of endometrial biopsies and curettings. Philadelphia: Lippincott-Raven; 1996. p. 209–12.Google Scholar
  6. 6.
    Ellenson LH, Ronnett BM, Soslow RA, Zaino RJ, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 6th ed. New York: Springer; 2011. p. 394–441.CrossRefGoogle Scholar
  7. 7.
    Lehman MB, Hart WR. Simple and complex hyperplastic papillary proliferations of the endometrium: a clinicopathologic study of nine cases of apparently localized papillary lesions with fibrovascular stromal cores and epithelial metaplasia. Am J Surg Pathol. 2001;25:1347–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Ip PP, Irving JA, McCluggage WG, Clement PB, Young RH. Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia. Am J Surg Pathol. 2013;37:167–77.CrossRefPubMedGoogle Scholar
  9. 9.
    Rekhi B, Menon S, Maheshwari A. Complex papillary hyperplasia of the endometrium- an uncommon case report, including cytopathological features and diagnostic implications. Diagn Cytopathol. 2015;43:163–8. doi: 10.1002/dc.23170.
  10. 10.
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.CrossRefPubMedGoogle Scholar
  11. 11.
    McCluggage WG. Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas. J Clin Pathol. 2002;55:321–5.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Silverberg SG, DeGiorgi LS. Histopathologic analysis of preoperative radiation therapy in endometrial carcinoma. Am J Obstet Gynecol. 1974;119:698–704.PubMedGoogle Scholar
  13. 13.
    Hunter JE, Tritz DE, Howell MG, DePriest PD, Gallion HH, Andrews SJ, et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynecol Oncol. 1994;55:66–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56:403–12.CrossRefPubMedGoogle Scholar
  15. 15.
    Baak JP, Wisse-Brekelmans EC, Fleege JC, van der Putten HW, Bezemer PD. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract. 1992;188:856–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19:1091–100.PubMedGoogle Scholar
  17. 17.
    Scholten AN, Creutzberg CL, van den Broek LJ, Noordijk EM, Smit VT. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. J Pathol. 2003;201:460–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Liao CL, Hsu JD, Lee MY, Kok LF, Li YJ, Wang PH, Yao CC, Han CP. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough? Virchows Arch. 2010;456:377–86.Google Scholar
  19. 19.
    Morrison C, Merati K, Marsh Jr WL, De Lott L, Cohn DE, Young G, Frankel WL. The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parameters. Appl Immunohistochem Mol Morphol. 2007;15:426–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Vang R, Barner R, Wheeler DT, Strauss BL. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol. 2004;23:223–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Deodhar KK, Rekhi B, Menon S. Female genital system. Uterus and cervix. In: Desai SS, Bal M, Rekhi B, Jambhekar NA, editors. Grossing of surgical oncology specimens. Tata Memorial Hospital; Mumbai, India:2011. p. 124–31.Google Scholar
  22. 22.
    American Joint Committee on Cancer. Corpus uteri. In: AJCC cancer staging manual, 7th ed. New York: Springer; 2010. p. 403.Google Scholar
  23. 23.
    NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Available at: Accessed 28 Mar 2015.
  24. 24.
    Kaku T, Tsuruchi N, Tsukamoto N, Hirakawa T, Kamura T, Nakano H. Reassessment of myometrial invasion in endometrial carcinoma. Obstet Gynecol. 1994;84:979–82.PubMedGoogle Scholar
  25. 25.
    Inoue Y, Obata K, Abe K, Ohmura G, Doh K, Yoshioka T, et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer. 1996;78:1447–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller PB, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group Study. Gynecol Oncol. 1991;40:55–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Duffy DL, Antill YC, Stewart CJ, Young JP, kConFab, Spurdle AB. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive families. Twin Res Hum Genet. 2011;14:111–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308.CrossRefPubMedGoogle Scholar
  29. 29.
    Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res. 2000;6:153–9.PubMedGoogle Scholar
  30. 30.
    Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999;18:138–43.CrossRefPubMedGoogle Scholar
  31. 31.
    Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24:2376–85.CrossRefPubMedGoogle Scholar
  32. 32.
    Garg K, Soslow RA. Endometrial carcinoma in women aged 40 years and younger. Arch Pathol Lab Med. 2014;138:335–42.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  • Bharat Rekhi
    • 1
  • Kedar K. Deodhar
    • 1
  • Santosh Menon
    • 1
  1. 1.Department of PathologyTata Memorial Hospital (TMH)MumbaiIndia

Personalised recommendations